Skip to content

Versius Gynecology Study

Prospective Clinical Study to Evaluate the Safety and Efficacy of Versius in Robot-Assisted Total Hysterectomy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07289295
Enrollment
46
Registered
2025-12-17
Start date
2025-07-25
Completion date
2026-04-14
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Robotic Assisted Hysterectomy and/or Salpingo-oophorectomy

Keywords

Versius, robotic surgery, hysterectomy, salpingo-oophrectomy, gynecology

Brief summary

The objective of this clinical trial is to expand the clinical evaluation of the safety and efficacy of Versius in gynaecology procedures of total robotic assisted hysterectomy and/or salpingo-oophorectomy

Interventions

Modular robotic system intended to assist in the accurate control of its surgical endoscopic instruments across a range of surgical procedures

Sponsors

CMR Surgical Ltd
Lead SponsorINDUSTRY
Uniwersyteckie Centrum Kliniczne im. prof. K. Gibińskego Śląskiego Uniwersytetu Medycznego w Katowicach
CollaboratorUNKNOWN

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Female, aged 22 years or above, who provided written informed consent to participate in the study. 2. Patient deemed suitable for minimally invasive total hysterectomy and/or Salpingo-Oophorectomy, for benign condition. 3. Patient with BMI ≤40.

Exclusion criteria

1. Patient unwilling to provide informed consent. 2. Medical contraindication for general anaesthesia or minimally invasive procedure. 3. Oncological cases, patient undergoing surgery or treatment for malignant disease. 4. Clinically assessed Uterus size of \> 14 pregnancy weeks (Estimated as \> 14-15 cm longitudinal diameter). 5. Patient participation in an interventional clinical study that could impact primary outcomes results. 6. Patient who falls into American Society of Anaesthesiologists (ASA) Class IV or above (Appendix A). 7. Uncontrolled hypertension, uncontrolled diabetes mellitus, or kidney failure.

Design outcomes

Primary

MeasureTime frameDescription
Success rateDay of surgeryRate of successful completion of robotic assisted surgery without unplanned conversion to other laparoscopic or open surgery.
Serious Adverse Event rateUp to 30 days post procedureRate of total serious adverse events

Secondary

MeasureTime frameDescription
Operative timeDay of surgerySurgical time from skin incision to skin closure
Estimated blood lossDay of surgeryAmount of blood estimated to be lost during surgery (in mL)
Intra-operative complicationsDay of surgeryComplications that occur during surgery
Blood transfusionsUp to post-surgical discharge, i.e. the date when patient is considered sufficiently recovered from surgery to leave hospital, expected to be at most up to 1 month after date of surgery, typically within a few daysNeed for blood transfusion during or after surgery as well as amount transfused
Unplanned instrument useDay of surgeryWhether unplanned use of non-Versius laparoscopic instruments during surgery occurs as well as at what surgical step
Device deficienciesDay of surgeryAny device deficiencies of Versius during surgery
Reoperation within 24 hours24 hours post-surgeryNeed for reoperation after initial surgery
Length of hospital stayUp to post-surgical discharge, i.e. the date when patient is considered sufficiently recovered from surgery to leave hospital, expected to be at most up to 1 month after date of surgery, typically within a few daysHospital stay in days from day of surgery until discharge
Adverse eventsUp to 30 days post-surgeryRate of adverse events
ReadmissionUp to 30 days post-surgeryHospital readmission after post-surgical discharge
Reoperation within 30 daysUp to 30 days post-surgeryNeed for reoperation as a result of interventional surgery itself or the indication for surgery
Mortality rateUp to 30 days post-surgery
Vaginal vault healing42 days post-surgeryVaginal vault healing as anticipated for patients that had total laparoscopic hysterectomy

Countries

Poland

Contacts

PRINCIPAL_INVESTIGATORKrzysztof Nowosielski, MD

Uniwersyteckie Centrum Kliniczne im. prof. K. Gibińskego Śląskiego Uniwersytetu Medycznego w Katowicach

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026